Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe and Extensive Deep-Partial and Full-Thickness Burn Wounds

NCT03695939 is registered in ClinicalTrials.gov with XenoTherapeutics, Inc. as lead sponsor.

NCT NCT03695939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03695939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe and Extensive Deep-Partial and Full-Thickness Burn Wounds
Lead sponsor
XenoTherapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 15, 2019
Completion date
December 30, 2023
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

deep full-thickness burn injury (disorder)